← Back to Analyst Consensus 
MXCT Buy
MAXCYTE, INC.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Mar 25, 2026 | Craig-Hallum | maintain | Buy → Buy | — | 54% |
| Aug 11, 2025 | BTIG | downgrade | Buy → Neutral | $0 | 52% |
| Aug 7, 2025 | William Blair | downgrade | Outperform → Market Perform | $0 | 48% |
| Mar 12, 2025 | Stifel | maintain | Buy → Buy | $9 | 53% |
| Apr 23, 2024 | Stephens & Co. | reiterate | Overweight → Overweight | $11 | 54% |
| Mar 13, 2024 | Stephens & Co. | reiterate | Overweight → Overweight | $11 | 54% |
| Mar 13, 2024 | BTIG | maintain | Buy → Buy | $8 | 52% |
| Nov 29, 2023 | Craig-Hallum | initiate | — → Buy | $7 | 54% |
| Oct 5, 2023 | Stephens & Co. | reiterate | Overweight → Overweight | $12 | 54% |
| Mar 28, 2023 | Stephens & Co. | reiterate | — → Overweight | $12 | 54% |
| Aug 15, 2022 | BTIG | maintain | — → Buy | $11 | 52% |
| Aug 24, 2021 | Stephens & Co. | initiate | — → Overweight | $19 | 54% |
| Aug 24, 2021 | William Blair | initiate | — → Outperform | $0 | 48% |
| Aug 24, 2021 | Cowen & Co. | initiate | — → Outperform | $0 | — |
| Aug 24, 2021 | Stifel | initiate | — → Buy | $18 | 53% |
| Aug 24, 2021 | BTIG | initiate | — → Buy | $22 | 52% |
Price Target Trend
Mar 31, 2026 Oct 26, 2026
EPS Estimates
+1y —
0y —
0q —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days